Law Firm Investigates Potential Claims Against Directors of Trius Therapeutics Inc

— Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Trius Therapeutics, Inc. (“Trius” or the “Company”) (Nasdaq- TSRX-News) relating to the proposed acquisition by Cubist Pharmaceuticals, Inc.


Under the terms of the transaction, Trius shareholders will receive only $13.50 in cash and a Contingent Value Right for an additional $2.00 in cash contingent on certain commercial sales milestones being met for each share of Trius stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Trius for not acting in the Company’s shareholders’ best interests in connection with the sale process. The transaction may undervalue the Company as Trius stock traded at $14.10 per share on July 31, 2013 and an analyst has set an $18.00 per share price target on Trius.

If you own shares of Trius common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at [email protected], by visiting, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Read more here:

Comments are closed.

Scroll to Top